REGENERON PHARMACEUTICALS, INC.
REGNNasdaqGSLatest results at a glance
Insights from the latest company results and reports · filed 30 Jul 2026
Quarterly Earnings Exceed Consensus
Reported non-GAAP EPS of $14.29 for the quarter ended June 30, 2026, exceeded the same-quarter consensus estimate of $10.21.
Dupixent Sales Reach Record
Dupixent global net sales, recorded by Sanofi, increased 38% to a new all-time high of $6.0 billion.
Manufacturing Interruption Resolved
Bulk manufacturing production at the Limerick, Ireland facility returned to normal levels by the end of the second quarter of 2026, following a temporary interruption that did not impact product availability.
Share Repurchase Activity
The company repurchased $2.0 billion of common stock during the six months ended June 30, 2026, with $2.5 billion remaining available under its repurchase programs.
Expanded Sanofi Alliance
[2026-10-01] Regeneron expanded its immunology alliance with Sanofi on terms that left the economics for its blockbuster drug Dupixent untouched, according to a financial news outlet.
Company research evidence
Checked financial measurements with the values, reporting periods and measurement basis shown together. This evidence is available independently of the AI report.
Loading evidence…
Deep Dive Research
Source-linked company research for REGN
Revenue segmentation
Loading segment disclosures…